scholarly journals Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis

Gut and Liver ◽  
2022 ◽  
Author(s):  
Kwangrok Jung ◽  
Jaewoo Park ◽  
Jae Hyup Jung ◽  
Jong-Chan Lee ◽  
Jaihwan Kim ◽  
...  
Keyword(s):  
Propensity Score ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Real World ◽  
Chemotherapy Regimen ◽  
Tract Cancer

Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer

2017 ◽  
Vol 103 (4) ◽  
pp. 345-352
Author(s):  
Jeong Il Yu ◽  
Hee Chul Park ◽  
Do Hoon Lim ◽  
Joon Oh Park ◽  
Young Suk Park ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcomes ◽  
Surgical Resection ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Chemotherapy Regimen ◽  
Significant Prognostic Factor ◽  
Free Survival ◽  
Tract Cancer ◽  
Locally Recurrent

Purpose The purpose of this study was to investigate the clinical outcomes and prognostic factors of concurrent chemoradiotherapy (CCRT) for locally recurrent biliary tract cancer (BTC) after curative surgical resection. Methods We performed a retrospective cohort study of patients with locally recurrent BTC treated with CCRT between October 2004 and December 2013. The study included and analyzed 42 patients with a history of curative-intent surgical resection of confirmed adenocarcinoma originating from the biliary tract. Results The median time to recurrence after surgery was 16.1 months (range, 4.5-77.8 months). Median follow-up after CCRT was 26.9 months (range, 5.2-81.9) with no grade 3 or higher gastrointestinal toxicities. Analysis of the first site of failure showed local progression (LP) developed in 20 patients (47.6%); among these, 16 (38.1%) had isolated LP. The median values were 15.8 months (range, 1.7-81.7) for LP-free survival (LPFS), 10.6 months (range, 1.7 - 81.7) for progression-free survival (PFS) and 41.2 months (range, 5.2-81.9) for overall survival (OS). Multivariate analysis showed that the level of pre-CCRT carbohydrate antigen (CA) 19-9 and the chemotherapy regimen were significant prognostic factors for LPFS and PFS; pT stage was the only significant prognostic factor for OS. Conclusions CCRT for locally recurrent BTC showed promising outcomes as a salvage modality, but LP was still frequent. The pre-CCRT CA 19-9 level and the chemotherapy regimen were prognostic factors for LPFS and PFS.

scholarly journals Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3507
Author(s):  
Hanna Lagenfelt ◽  
Hakon Blomstrand ◽  
Nils O. Elander
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Real World ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Real Life ◽  
Phase Iii ◽  
Combination Regimen ◽  
Neutrophil Lymphocyte Ratio ◽  
Tract Cancer

Background: Gemcitabine and oxaliplatin (GemOx) is a standard combination regimen in advanced biliary tract cancer (BTC). There is limited evidence on its efficacy and safety in real life. Methods: A retrospective multicentre cohort study in the South East Region of Sweden, covering nine years (2011–2020) and three hospitals where GemOx was treatment of choice, was designed. Clinicopathological prognostic parameters were explored. Results: One hundred and twenty-one patients with advanced BTC were identified. Median overall and progression-free survival (OS and PFS) were 8.9 (95% CI = 7.2–10.6) and 5.3 (95% CI = 3.8–6.7) months. Performance status according to Eastern Cooperative Oncology Group (PS according to ECOG) 1–2 and primary gallbladder carcinoma were independent predictors for poor OS. PS and derived neutrophil/lymphocyte ratio were predictive for PFS. The most common severe type of myelosuppresion was grade 3 neutropenia that was recorded in 8%. Fifty-three (43.8%) experienced at least one episode of unplanned hospitalisation. One hundred and seventeen (97%) received oxaliplatin with lower dosage than was utilized in previous phase III trials (80–85 vs. 100 mg/m2) and a majority received further dose reductions of oxaliplatin and/or gemcitabine. Conclusion: The outcome of GemOx in advanced BTC appears comparable in controlled trials and real-world contexts. A lower dose of oxaliplatin seems more tolerable without compromising the outcome.

Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis

2021 ◽  
pp. 1-10
Author(s):  
Roberto Filippi ◽  
Francesco Leone ◽  
Lorenzo Fornaro ◽  
Giuseppe Aprile ◽  
Andrea Casadei-Gardini ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Real World ◽  
Case Series ◽  
Cancer Case ◽  
Tract Cancer

scholarly journals Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Florian Moik ◽  
Jakob M. Riedl ◽  
Thomas Winder ◽  
Angelika Terbuch ◽  
Christopher H. Rossmann ◽  
...  
Keyword(s):  
Propensity Score ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Systemic Chemotherapy ◽  
Propensity Score Analysis ◽  
Second Line ◽  
Tract Cancer ◽  
Score Analysis
Sign in / Sign up

Export Citation Format

Share Document